Blockbuster Pathology Deal Sees Japan’s Miraca Holdings Pay $725 Million to Acquire Caris Diagnostics

Deal may be just the first of more clinical laboratory acquisitions in the U.S by Japan’s largest medical lab testing company

Pathology and clinical laboratory testing companies continue to go global and last week’s big acquisition in anatomic pathology gave one of Japan’s biggest clinical laboratory companies an important foothold in the United States.

Miraca Holdings Inc. (TYO: 4544.T) of Tokyo, Japan, announced that it would acquire the anatomic pathology business of Caris Life Sciences, Inc., of Irving, Texas. Miraca says the purchase is the first ever by a Japanese company of a clinical laboratory testing company in the United States.

Prices of Clinical Pathology Laboratories Are Rising Due to Buyer Demand

Conference on May 5 about clinical laboratory and pathology mergers and acquisitions

For owners and sellers of clinical laboratories and anatomic pathology groups in the United States, the past six months have been rosy times. That’s because buyers have stepped up and paid strong prices for the medical laboratory companies and pathology testing firms that came to market during this time.

Experts predict that merger and acquisition (M&A) activity in the clinical laboratory industry will continue to be robust. Several factors reinforce this optimistic prediction.


Australia’s Government Launches Review of Clinical Laboratory Testing Fees

Sonic Healthcare stock slides on announcement of Medicare Australia funding changes

In Australia, funding for pathology services and clinical laboratory testing is now undergoing review by the government health service. Last month, when news broke that the Australian Department of Health and Ageing was initiating a review of pathology funding, there was an immediate response by the stock market, as reflected in the lower price for shares of Sonic Healthcare, Ltd. (ASX:SHL), Australia’s largest provider of pathology services and clinical lab testing.


Clinical Labs Make Money by Using Revenue Cycle Management

Management Tool Contributes to More Collected Revenue, Higher Sales Prices

Revenue Cycle Management (RCM) is hitting the radar screen at the nation’s best-managed clinical laboratories. That’s because shrinking reimbursement makes it imperative for clinical labs and pathology groups to collect every dollar legally due for the lab testing services they provide. RCM is a proven management tool for reducing unpaid claims and unlocking more productivity in the coding/billing/collections process.

“Revenue Cycle Management for laboratories encompasses all the administrative and management functions that contribute to the capture, and collection of revenue associated with lab testing services,” observed Lale White, CEO of Xifin, Inc. of San Diego, California. White has been an acknowledged national expert in laboratory coding, billing, and collections for more than two decades.


Long-Awaited Lab Contract Transition in New Zealand Happens Next Monday

Labtests succeeds Sonic’s DML as the primary lab test provider in Auckland area

One of the world’s most interest experiments in government contracting for clinical laboratory testing services is unfolding in Auckland, New Zealand. Next Monday, September 7, Labtests will assume full responsibility for testing approximately 12,000 patients per day in a brand-new laboratory facility that has only conducted testing on a limited basis since August 10, 2008.

On that same day, Diagnostic Medlab’s (DML) existing contract with the District Health Boards in greater Auckland will terminate. Earlier, on August 18, DML’s parent company, Sonic Healthcare Ltd. (ASX:SHL) of Sydney, Australia, announced plans to shutter DML’s laboratory facility and write-off its Auckland-based business division.